Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...
BioCardia completes enrollment for heart therapy trial
BCDA], a developer of cellular therapies for cardiovascular diseases with a current market capitalization of $12 million, has announced the completion of enrollment and dosing for the low-dose cohort ...
BioCardia completes enrollment in low dose cohort in CardiALLO Phase I/II trial
BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy ...